Genprex Inc., a clinical-stage gene therapy company, is focused on developing for these patients with serious medical conditions and unmet need new and better treatment options that are life-changing.
Reprogramming the course of cancer and diabetes, Austin-based Genprex is on the cutting edge of technologies to address the biggest health concerns
Genprex is advancing its novel gene therapies for large patient populations with cancer and diabetes who currently have limited treatment options
Genprex, a clinical-stage gene therapy company, has recently released groundbreaking data from a non-human primate study evaluating a novel gene therapy to treat Type 1 diabetes.
With results of an animal study published in February 2023, Genprex aims to add credibility to another genome editing approach in the hunt for a functional cure to T1D.
Results show statistically significant decreases in insulin requirements, increases in c-peptide levels and improvements in glucose tolerance compared to baseline
Technologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of this Disease for the Millions of Patients Around the World with Type 1 or Type 2 Diabetes
Exciting Data from University of Pittsburgh Researchers in Non Human Primates that Underpins Genprex’s Gene Therapy Program in Diabetes to be Showcased
Technology for modulating autoimmunity expands intellectual property portfolio
Groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells is potentially applicable to both Type 1 and Type 2 diabetes
Designed and Secured by Barsec